logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
J

John F. Kurland

AstraZeneca
H指数:25
被引数:6,119

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer)

HIMALAYA研究中曲美木单抗联合度伐利尤单抗治疗不可切除肝细胞癌（肝癌）的五年总生存率更新报告

Future Oncology
IF2.6
2026-05-100
OAAI
Lorenza Rimassa; Stephen L. Chan; Bruno Sangro; George Lau; Masatoshi Kudo; Maria Reig; Valeriy Breder; Min-Hee Ryu; Yurii Ostapenko; Wattana Sukeepaisarnjaroen; Maria Varela; David Tougeron; Oxana V. Crysler; Mohamed Bouattour; Tu Van Dao; Vincent C. Tam; Adilson Faccio; Junji Furuse; Long-Bin Jeng; Yoon Koo Kang; Robin K. Kelley; John F. Kurland; Kavitha Balaji; Ghassan K. Abou-Alfa
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC

HIMALAYA研究五-year总体生存率更新：曲美木单抗联合度伐利尤单抗治疗不可切除性HCC

Journal of Hepatology
IF33
2025-04-110
OAAI
Lorenza Rimassa; Stephen L. Chan; Bruno Sangro; George Lau; Masatoshi Kudo; Maria Reig; Valeriy Breder; Min-Hee Ryu; Yuriy Ostapenko; Wattana Sukeepaisarnjaroen; Maria Varela; David Tougeron; Oxana V. Crysler; Mohamed Bouattour; Tu Van Dao; Vincent C. Tam; Adilson Faccio; Junji Furuse; Long-Bin Jeng; Yoon Koo Kang; Robin K. Kelley; Michael J. Paskow; Di Ran; Ioannis Xynos; John F. Kurland; Alejandra Negro; Ghassan K. Abou-Alfa
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

tremelimumab联合durvalumab治疗不可切除肝细胞癌的III期喜马拉雅研究的四年总生存期更新

ANNALS OF ONCOLOGY
IF65.4
2024-05-0139
OA
Sangro, B.; Chan, S. L.; Kelley, R. K.; Lau, G.; Kudo, M.; Sukeepaisarnjaroen, W.; Yarchoan, M.; De Toni, E. N.; Furuse, J.; Kang, Y. K.; Galle, P. R.; Rimassa, L.; Heurgue, A.; Tam, V. C.; Van Dao, T.; Thungappa, S. C.; Breder, V.; Ostapenko, Y.; Reig, M.; Makowsky, M.; Paskow, M. J.; Gupta, C.; Kurland, J. F.; Negro, A.; Abou-Alfa, G. K.
Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

durvalumab联合5-氟尿嘧啶、亚叶酸、奥沙利铂和多西他赛 (FLOT) 治疗可切除胃癌和胃食管交界癌 (GC/GEJC) 的病理完全缓解 (pCR): 全球III期马特洪峰研究的中期结果

ANNALS OF ONCOLOGY
IF65.4
2023-11-016
PRE
Oh, D-Y.; Janjigian, Y. Y.; Al-Batran, S-E.; Wainberg, Z. A.; van Cutsem, E.; Molena, D.; Muro, K.; Hyung, W. J.; Wyrwicz, L. S.; Omori, T.; Moehler, M.; Garrido, M.; Cunha Sousa Oliveira, S.; Liberman, M.; Castro Oliden, V.; Bilici, M.; Kurland, J.; Xynos, I.; Mann, H.; Tabernero, J.
Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
ANNALS OF ONCOLOGY
IF65.4
2023-10-0133
OAAI
Janjigian, Y. Y.; Al-Batran, S-E.; Wainberg, Z. A.; Van Cutsem, E.; Molena, D.; Muro, K.; Hyung, W. J.; Wyrwicz, L. S.; Oh, D. Y.; Omori, T.; Moehler, M.; Garrido, M.; Oliveira, S. Cunha Sousa; Liberman, M.; Oliden, V. Castro; Bilici, M.; Kurland, J. F.; Xynos, I.; Mann, H.; Tabernero, J.
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer
FUTURE ONCOLOGY
IF2.6
2023-09-257
OA
Oh, Do-Youn; He, Aiwu Ruth; Qin, Shukui; Chen, Li-Tzong; Okusaka, Takuji; Vogel, Arndt; Kim, Jin Won; Suksombooncharoen, Thatthan; Lee, Myung Ah; Kitano, Masayuki; Burris, Howard; Bouattour, Mohamed; Tanasanvimon, Suebpong; McNamara, Mairead G.; Zaucha, Renata; Avallone, Antonio; Tan, Benjamin; Cundom, Juan; Lee, Choong-kun; Takahashi, Hidenori; Ikeda, Masafumi; Chen, Jen-Shi; Wang, Julie; Makowsky, Mallory; Rokutanda, Nana; Zotkiewicz, Magdalena; Kurland, John F.; Cohen, Gordon; Valle, Juan W.
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

喜马拉雅研究的简明语言摘要: tremelimumab和durvalumab治疗不可切除的肝细胞癌 (肝癌)

FUTURE ONCOLOGY
IF2.6
2023-09-0615
OA
Abou-Alfa, Ghassan K.; Lau, George; Kudo, Masatoshi; Chan, Stephen L.; Kelley, Robin Kate; Furuse, Junji; Sukeepaisarnjaroen, Wattana; Kang, Yoon Koo; Dao, Tu Van; De Toni, Enrico N.; Rimassa, Lorenza; Breder, Valeriy; Vasilyev, Alexander; Heurgue, Alexandra; Tam, Vincent C.; Mody, Kabir; Thungappa, Satheesh Chiradoni; Ostapenko, Yurii; Yau, Thomas; Azevedo, Sergio; Varela, Maria; Cheng, Ann-Lii; Qin, Shukui; Galle, Peter R.; Ali, Sajid; Gupta, Charu; Makowsky, Mallory; Kurland, John F.; Negro, Alejandra; Sangro, Bruno
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
ANNALS OF ONCOLOGY
IF65.4
2023-03-0161
OA
Psyrri, A.; Fayette, J.; Harrington, K.; Gillison, M.; Ahn, M. -J.; Takahashi, S.; Weiss, J.; Machiels, J. -P.; Baxi, S.; Vasilyev, A.; Karpenko, A.; Dvorkin, M.; Hsieh, C. -Y.; Thungappa, S. C.; Segura, P. P.; Vynnychenko, I.; Haddad, R.; Kasper, S.; Mauz, P. -S.; Baker, V.; He, P.; Evans, B.; Wildsmith, S.; Olsson, R. F.; Yovine, A.; Kurland, J. F.; Morsli, N.; Seiwert, T. Y.
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours
EUROPEAN JOURNAL OF CANCER
IF7.1
2013-05-0119
PREAI
Soria, Jean-Charles; Baselga, Jose; Hanna, Nasser; Laurie, Scott A.; Bahleda, Rastislav; Felip, Enriqueta; Calvo, Emiliano; Armand, Jean-Pierre; Shepherd, Frances A.; Harbison, Christopher T.; Berman, David; Park, Jong-Soon; Zhang, Steven; Vakkalagadda, Blisse; Kurland, John F.; Pathak, Ashutosh K.; Herbst, Roy S.

研究方向

暂未获取到该数据
M
Masatoshi Kudo
H 指数:143论文数:2,840被引数:12.5万
R
Robin Kate Kelley
H 指数:94论文数:510被引数:7.9万
V
Vincent C. Tam
H 指数:23论文数:129被引数:6,808
W
Wattana Sukeepaisarnjaroen
H 指数:26论文数:136被引数:4,465
A
Alejandra Negro
H 指数:19论文数:74被引数:3,693
G
Ghassan K. Abou‐Alfa
H 指数:77论文数:754被引数:2.9万
R
Raymond E. Meyn
H 指数:53论文数:293被引数:8,463
T
Tu Van Dao
H 指数:15论文数:82被引数:2,880
J
Junji Furuse
H 指数:75论文数:731被引数:2.8万
Y
Yoon‐Koo Kang
H 指数:93论文数:864被引数:6.0万